TILRAY (TLRY)
EARNINGS RELEASE - AUGUST 10 (AMC)
EARNINGS EXPECTATIONS:
THIS QTR: EPS: -.27/share REV: 55.02/M
___________________________________________________________
LAST QTR: EPS: -.45/share ACTUAL: -1.73/share (MISS)
____________________________________________________________
NEXT QTR: EPS: -.24/share REV: 60.15/M
____________________________________________________________
FULL YR: EPS: -2.27/share REV: 237.68/M
____________________________________________________________
BEAT/MISS RECORD: 14% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) -8.66, -15.3, -3.01
EXPECTED JUMP MOVE THIS QUARTER: 10-12%
——–
*** With market volatility at extremes there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before tradin
Links To Latest News and Headlines
(Bloomberg) — Canadian cannabis titan Tilray Inc. fell for a third straight day, surrendering much of a rally posted earlier this week after earnings that were buoyed by acquisitions and a rebranding — moves aimed at strengthening its global reach in the face of stiff competition at home.Most Read from BloombergDjokovic Loses Shot at Tennis History as Australia Deports StarOne of the World’s Wealthiest Oil Exporters Is Becoming UnlivablePutin’s Troops Wouldn’t Get Cheers in This Once Pro-Russi
Tilray (NASDAQ:TLRY) has been one of the most disappointing cannabis companies . TLRY stock initially shot up to $300 following its initial public offering (IPO). Since then, however, the stock has lost roughly 97% of its value. Source: Jarretera / Shutterstock.com The company has experienced a comedy of errors. The Canadian retail cannabis market took far longer to develop than expected. Tilray was plagued with excess inventory, and it made questionable capital allocation decisions. The company
Cannabis stocks and ETFs were massively downbeat in 2021. However, strong sales backdrop, growing medical usage and still-alive chances of a federal approval may cause a bounce back in pot ETFs in 2022.
» Microsoft hires Apple chip veteran, cannabis compounds may prevent COVID infection, TPG prices IPO
Yahoo Finance’s Julie Hyman breaks down the leading headlines on Microsoft chip development, a new cannabis study tied to COVID-19, and private equity firm TPG.
The descent for Canadian marijuana stocks continued last year, as expectations dimmed for cannabis reform in the U.S.
StockJumpers analysis and trade plans are finalized and uploaded generally one house before market cloase (3PM EST) for most events unless noticed.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
Members who are too busy to manual trade can use Trade Assist. For more information visit here
| Avg Daily Volume: 9,055,059 Market Cap: 946.45M Sector: Consumer Durables Short Interest: 19.43 |
Ticker delayed 20 minutes
NOTICE: All material on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.
by Team Stockjumpers